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fusion, 4 samples harbored huntingtin interacting pro-
tein 1 ALK (HIP1-ALK) fusion, 1 sample harbored kinesin
light chain 1 ALK (KLC1-ALK) fusion, and the remaining
16 samples harbored novel fusion variants. Of the 133
EML4-ALK positive samples, 55 samples harbored
E13:A20 variants (Variant 1), 55 samples harbored
E6:A20 (Variant 3), 16 samples harbored E20:A20
(Variant 2), 4 samples harbored E18:A20 and 3 samples
harbored E2:A20.
Conclusion: This is the largest molecular epidemio-
logical study to describe ALK fusion variants in East
Asian LUAC patients. EML4 is the most common fusion
partner of ALK gene. About 84% of ALK fusion positive
patients harbor EML4-ALK, and 5.7% harbor non-
EML4-ALK fusions. The remaining 10% harbor fusions
with unknown partners. For EML4-ALK, E13:A20 and
E6:A20 are the most common variants, comprising
more than 80% of EML4-ALK fusion. E20:A20, E18:A20
and E2:A20 are also identiﬁed in East Asian patients.
The constitution of EML4-ALK fusion variants is similar
to the previous reports of patient cohorts in western
countries. All the ALK fusion variants mentioned
should be included in the LUAC fusion screening
assays.
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The hyperglycolytic, hypermetabolic activity of cancer
cells contributes to a ‘stressful’ local tumor environ-
ment in which cells compete for limited nutrients while
being bathed in excessive metabolic waste, including
high levels of lactic acid. Cells within a tumor undergo a
period of environmental stress that is most pronounced
when the growing tumor cell mass exceeds its vascu-
lature, further limiting nutrients and increasing the
accumulation of waste. This can be viewed as a selec-
tion step in which only those cells, both cancer and
stroma, that are best adapted to survive the stress
maintain the ability to proliferate. The aim of this study
was to characterize the molecular basis for the survival
of non-small cell lung cancer (NSCLC) cells when
exposed to environmental stress. To accomplish this
objective we used an in vitro culture system designed
to recapitulate the environmental stressed conditions
of depleted nutrients and accumulated waste experi-
enced by cells within tumors. In examining a panel ofhuman NSCLC cell lines, we unexpectedly found that the
status of RAS was a more important determinant for
surviving environmental stress than the status of p53.
Lines with activating RAS mutations (KRAS or NRAS)
were better poised to survive severe environmental
stress, independent of p53 status. In detailed molecular
cell biological studies comparing a NSCLC cell line wild
type for p53 with an activating KRAS mutation to a
NSCLC cell line mutant for p53 without an activating
RAS mutation, we found that survival correlated with
the level of autophagy in the unstressed cells. Cells that
survived stress had low basal levels of autophagy that
increased upon stress, whereas those that did not sur-
vive stress had elevated autophagy in the absence of
stress that was increased further with the stress. Basal
activation of AKT (also known as Protein kinase B) was
higher in unstressed KRAS cells than in p53 mutant
cells. Active AKT inhibits autophagy, thereby likely
explaining the lower basal level of autophagy in KRAS
mutant cells. In quantitative ﬂuorescence microscopy
studies of living cells, we demonstrated that p53
mutant NSCLC cells, in addition to having elevated
autophagy, have more acidic and motile lysosomes,
phenotypes correlated with increased lysosomal activ-
ity. This basal ‘lysosomal activation’ is likely linked to
the elevation of basal autophagy. Based on these studies
we conclude that the ability of cells to maintain low
autophagy in the absence of stress and to activate
autophagy in response to stress are important for
enhanced survival when cells are challenged with
environmental stress. Activated RAS, via regulation of
nutrient absorption pathways, might make cells less
dependent on stress-activated mechanisms, such as
autophagy, to fulﬁll nutrient needs. Furthermore, loss of
p53 in the absence of KRAS activation results in an
increased basal autophagy, which when further
increased by environmental stress, results in decreased
cell survival. These data suggest that the role of auto-
phagy in cancer cell survival in the context of envi-
ronmental stress is linked to speciﬁc oncogenic
mutations. This ﬁnding has signiﬁcant implications for
targeting autophagy in the treatment of lung cancer.Unique roles for Akt isoforms in
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Lung cancer is the leading cause of cancer-related mor-
talities worldwide and 5 year survival rates are typically
<20%. As traditional therapies are largely ineffective
S34 Journal of Thoracic Oncology Vol. 11 No. 2Sagainst advanced lung cancer, molecular targets are be-
ing explored. An emerging molecular target for lung
cancer is the signaling molecule Akt as it is frequently
activated in lung cancer. Akt is activated by a number of
growth factor receptors and mediates processes such as
proliferation, survival, migration, and metabolism. Three
Akt isoforms (Akt1-3) exist in mammals and it remains
unclear whether each isoform has distinct functions. To
evaluate the function of Akt isoforms in lung cancer, a
transgenic mouse model (SPC-IGFIR) where lung tumors
were induced by elevated expression of IGF-IR and
subsequent activation of Akt was used. SPC-IGFIR mice
were mated with Akt1-/- or Akt2-/- mice to produce SPC-
IGFIR mice lacking either Akt1 or Akt2. Lung tumori-
genesis was suppressed in SPC-IGFIR/Akt1-/- mice and
enhanced in SPC-IGFIR/Akt2-/- mice. Lung tumor cells in
SPC-IGFIR/Akt2-/- mice appeared to inﬁlitrate the lungs
to a greater extend than either SPC-IGFIR or SPC-IGFIR/
Akt1-/- tumor cells which had a more nodular appear-
ance. RNA sequencing revealed a number of genes and
transcripts differentially expressed in the SPC-IGFIR/
Akt2-/- lung tumors and several of these genes have been
implicated in human NSCLC. Using 2 human NCSLC cell
lines it was determined that an AKT1 selective inhibitor
impaired cell survival more than an AKT2 inhibitor or a
pan-AKT inhibitor. These results suggest that inhibition
of Akt1 may represent a therapeutic strategy for lung
cancer.
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Purpose: Although long-term survival rates for early
stage lung cancer are high, most patients are diagnosed
with advanced stage disease. The National Lung
Screening Trial demonstrated a survival beneﬁt with
annual low-dose chest CT (LDCT) in patients at high risk,
despite a false positive rate of 96%. Most attempts atdevelopment of blood-based early detection for lung
cancer employ panels of several biomarkers, which are
susceptible to overﬁtting and poor reproducibility on
new samples. We hypothesized that a single biomarker-
based approach would be more effective.
Methods: Whole blood was collected in PAXgene tubes
from 289 patients under IRB-approved protocols at four
institutions. This included 231 retrospective specimens
and 58 specimens collected prospectively. We collected
smoking history, cancer diagnosis, age and gender for all
patients. Due to the use of a single marker and low risk
of overﬁtting, the training set consisted of only 29 pa-
tients. The validation set consisted of 133 non-small cell
lung cancer, 14 small cell lung cancer and 113 cancer-
free patients. A total of 11 patient cohorts were created
based on combination of cancer histology and smoking
history. RNA was extracted, and the expression of formyl
peptide receptor 1 (FPR1) and a reference gene were
quantiﬁed by an automated one-step Taqman RT-PCR
assay.
Results: In the validation set, elevated levels of FPR1
mRNA in whole blood demonstrated a sensitivity of 55%
and a speciﬁcity of 87% for lung cancer detection.
Among prospectively collected specimens, FPR1 mRNA
had a sensitivity of 68% and speciﬁcity of 89%. The
sensitivity of prospective samples was signiﬁcantly
higher than retrospective samples (p¼0.018) while the
speciﬁcity was unchanged. We observed that longer
times between collection and refrigeration/freezing of
samples tended to yield negative results. This time was
much shorter on prospective samples, and this likely
explains the increased sensitivity. No signiﬁcant differ-
ence in sensitivity was observed based on histology
(including small cell vs. non-small cell) or cancer stage.
Results from patients with benign nodules were similar
to healthy volunteers. We used multiple data mining
techniques and found no meaningful relationship be-
tween our test results and any clinical characteristic
other than lung cancer diagnosis, including age, smoking
history, and gender.
Discussion: FPR1 mRNA levels in whole blood can iden-
tify the presence of lung cancer with high accuracy. A
single-marker test is less prone to overﬁtting of datawhen
compared to amulti-marker test created through complex
data mining algorithms, and thus is more likely to be
reproducible. The use of a training/validation set strategy
further increases likelihood that results will be repro-
duced in follow-on studies. Using FPR1 as a reﬂex test for
suspicious lung cancer screening CT scans may have the
potential to increase the positive predictive value (PPV).
Future planned studies will explore the source of this
biomarker and evaluate its effectiveness in augmenting CT
scans for patients undergoing lung cancer screening.
